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Abstract
Background MicroRNAs (miRNAs) are short single-
stranded RNA molecules that regulate gene expression
post-transcriptionally. Several hundred miRNAs exist in the
mammalian genome and regulate developmental processes,
cell cycle, and survival.
Methods In this review, we highlight general modes ofmiRNA
function and relate them to how such regulation can be
beneficial for immune homeostasis and the prevention of
autoimmune diseases.Wehighlight examples of experimentally
verified miRNA function and their target genes in the immune
system and place them in context of concepts relevant to an
understanding of autoimmune pathogenesis. Where available,
we refer to clinical correlations. Finally, we speculate how
emerging knowledge about miRNA function in the immune
system might be used diagnostically and therapeutically.
Keywords MicroRNA . autoimmunity . dicer .
immune homeostasis . regulatory T cells (Treg)
Introduction
The regulation of protein expression by (small) RNAs was first
observed ∼25 years ago. In the mid-1980s, several studies
reported that transgenic antisense RNA could inhibit gene
expression in Drosophila, mammalian cells, and plants [1–4].
This phenomenon was termed post-transcriptional gene silenc-
ing in the plant biology world. In the 1990s, it was
demonstrated that the worm Caenorhabditis elegans uses an
endogenous small RNA to inhibit the synthesis of a protein
through sequence complementarity to the 3′ untranslated region
(3′ UTR) of the targeted mRNA [5]. Fire and Mello discovered
that exogenous, ∼21–23 nucleotide double-stranded RNAs
(siRNAs), interfered with protein-encoding genes and coined
the term RNA interference (RNAi) [6]. A class of endogenous,
small single-stranded non-protein-coding RNA genes, compris-
ing hundreds of members, was termed microRNAs (miRNA)
[7–9]. Today, this class of genes is thought to function as
important regulators of development, cell differentiation,
proliferation, and cell death in most multi-cellular organisms
[10–12]. Other classes of small RNAs that are generated via
different molecular machinery have been described, although
their role in the immune regulation is less clear [13–17].
Mammalian miRNAs are generated as long primary
transcripts called pri-miRNAs which can encode a single
miRNA or a cluster of several polycistronic miRNAs. The
microprocessor complex formed by Drosha/DGCR8 and
other proteins recognizes the pri-miRNAs and processes
them into. The resulting short double-stranded RNA
molecules are separated into single-stranded molecules of
which one (guide strand) is loaded into the RNA- induced
silencing complex formed by members of the Argonaute
(Ago) family, Dicer, TRBP, and others. miRNAs pair with
complementary sequences of their target mRNA through a
region called “seed” at the 5′ end of the miRNA. Other
regions and determinants have been described recently that
guide miRNA function as well [18–20].
The bulk of current studies suggest that the large majority of
miRNAs inhibit protein-coding genes. However, there are a
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few reported exceptions where miRNAs positively affect gene
expression [21–23]. How inhibition of protein expression is
achieved is still a matter of debate. mRNA degradation and
translational inhibition have been put forth [24–28] with themost
recent data, suggesting that the effect on mRNA degradation is
more pronounced than translational inhibition [26].
Despite intensive research, miRNA biogenesis and the
maintenance of a functional miRNA pool is still incompletely
understood [29]. Particular proteins can regulate the gener-
ation of subsets of miRNAs [30] and active degradation of
miRNAs has been described in plants and worms [31, 32].
Interestingly, several cytokines with known important func-
tions in the immune system can control miRNA maturation
for a subset of miRNAs at the post-transcriptional level. In
this regard, transforming growth factor beta (TGF-ß) and
bone morphogenetic proteins (BMPs) have been shown to
regulate miRNA processing in human vascular smooth
muscle cells [33]. Since it is known that TGF-ß can induce
FoxP3 in conventional T cells, it will be interesting to
determine if TGF-ß controls the high miR-21 expression
observed in regulatory T cells (Treg) which are highly TGF-ß
dependent and depend on Dicer for FoxP3 induction (ref
[34] and Jeker & Bluestone, unpublished).
It is now clearly established that miRNAs play important
functions in the immune system [35]. Convincing data has
come from studies where individual miRNAs were over-
expressed or disrupted and miRNA binding sites in target
mRNAs have been genetically deleted. These studies
demonstrated that the miR-17∼92 cluster, miR-150, miR-
155, and miR-181a are important regulators of B and T cell
development and play crucial roles for the establishment of
a functional adaptive immune system [36–46].
Excellent comprehensive reviews on individual miRNAs,
cell systems, or diseases have recently been published [35, 47–
50]. Thus, in this review, we will cover general principles how
miRNAs function as rheostats that control overall immune
homeostasis. We will discuss modes of miRNA action and
highlight examples of how the immune system relies on
miRNAs to control lymphocyte development, differentiation,
and control of immune responses. Although we will focus on
miRNAs expressed in lymphocytes, we speculate that the
general principles described will be applicable to the important
role of these small RNAs throughout the immune system [35,
51–53]. Finally, we attempt to highlight how the emerging
knowledge of miRNA function in the immune system might
be exploited diagnostically and therapeutically.
Functional Evidence for the Importance of RNAi
Machinery in Lymphocytes and Autoimmunity
The discovery of several key proteins in the biogenesis of
small RNAs (Drosha/DGCR8, Dicer, and Argonautes in
mammals) have allowed the simultaneous non-selective or
partially selective ablation of hundreds of miRNAs while
leaving protein-coding genes intact [29, 54–56]. Although
constitutive deletion of Dicer is embryonic lethal in mice
[10] and zebrafish [55], selective deletion of Dicer [57, 58],
Drosha [59], DGCR8 [60, 61], or Ago2 [56] in individual
immune subsets has been used to determine that miRNAs
are critical for B, NK, NKT, and T cell development,
function, and lineage stability of terminally differentiated
lymphocytes [59, 62–68]. Dicer ablation in T cells
demonstrated its essential role in αβ-T cell receptor
(TCR) thymocyte development as Lck-cre-mediated, T
cell-specific, Dicer deficiency led to severe thymic hypo-
plasia. Although there were no apparent changes in the
CD4/CD8 lineage choice [65], the severity of this thymic
dysplasia prevented a more detailed analysis of the
peripheral T cell pool. Dicer ablation using a CD4-cre
transgene, which is expressed at a later developmental time
point, did not affect thymocyte maturation but resulted in
mild T cell lymphopenia as Dicer-deficient T cells under-
went apoptosis and proliferated less than wild type T cells
[34, 66]. However, after primary stimulation, IL-2 produc-
tion by Dicer-deficient T cells was normal but demonstrated
reduced mRNA stability resulting in rapid decay after
prolonged culture. In contrast to Dicer deletion in B cells,
the Dicer-deficient T cells could not be rescued with a bcl-2
transgene, suggesting that Dicer was controlling more than
the apoptotic program [34, 62].
Most importantly, T cell-specific Dicer-deficiency led to
multiorgan autoimmunity of lung, liver, and colon and
lymphoproliferative disease with lymphadenopathy and
splenomegaly [34] concordant with a significant reduction
of thymically derived, natural regulatory T cells (nTreg).
Thus, three groups selectively ablated RNAi key enzymes in
Treg using FoxP3-cre transgenes [59, 67, 68]. These studies,
using different cre transgenic lines, showed largely over-
lapping results and demonstrated phenotypes resembling the
scurfy phenotype where Treg completely lacks FoxP3
function [69]. Disease onset was very early with most mice
dying within a few weeks of life. Deletion of Dicer using the
CD4-cre strategy resulted in organ infiltration only after 3–
4 months with incomplete penetrance [34, 59]. This was
most likely due to combined autoimmunity and immuno-
deficiency resulting from Dicer ablation in all CD4 and
CD8 T effector cells, as illustrated by the reduced capability
to induce IL-17 in vitro [34].
In the experimental system used by Liston et al., female
mice harbor Dicer-sufficient and Dicer-deficient Treg
populations due to X-inactivation [68]. These mice
remained healthy, indicating that tolerance could be
preserved if a fraction of Treg cells remained wild type.
The proportion of Dicer-sufficient and Dicer-deficient Treg
cells was equal in thymus but favored wild type Tregs in
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the periphery. There was no proliferation defect. Treg cells
remained anergic, but in vitro suppressive capacity was
somewhat impaired, and in vitro TCR ligation led to
decreased proliferation and increased apoptosis in the
Dicer-deficient Treg. Importantly, Treg cells isolated from
sick mice lost their hallmark anergy and were completely
devoid of in vitro suppressive capacity [68]. These results
indicate that miRNAs might be more important under
stress conditions like inflammation than under homeostatic
conditions.
Our studies provided insights into Treg lineage instability
in the absence of Dicer [67]. Using genetic lineage tracing,
we demonstrated that miRNA-deficient Treg can survive,
but lose FoxP3 to a significant degree with at times >50%
of Treg cells having lost FoxP3 expression. Furthermore,
we demonstrated that about 5% of actively FoxP3 tran-
scribing Dicer-deficient Treg cells had lost their anergic
phenotype and begun to secrete the pathogenic cytokine
IFN-γ. Thus, miRNA-deficient Treg cells lose lineage
identity and take on Th1-like features. Finally, the indistin-
guishable phenotype between Treg-specific Dicer and
Drosha ablation underscores the conclusion that indeed
canonical miRNAs are critical to Treg homeostasis because
Drosha is specific for miRNA biogenesis while Dicer also
processes other classes of small RNAs [29, 59].
Mechanistically, Dicer-deficient T cells showed deficient
induction of FoxP3 by TGF-β in vitro and IL-17 by TGF-β
and IL-6 [34]. Of note, it appeared that the FoxP3
fluorescence was lower in the absence of Dicer [34] and
the Dicer-deficiency altered T cell differentiation. Dicer-
deficient cells were prone to develop a Th1 phenotype in
various settings including normally Th2-driving conditions
[66]. Thus, Dicer regulates peripheral terminal T cell
differentiation and lineage stabilization and miRNA defi-
ciency leads to severely skewed cytokine profiles. Most
importantly, unlike most Dicer-deficient cell types, which
showed decreased cell proliferation and viability, only T
cell-specific Dicer deletion led to autoimmunity.
In summary, miRNAs are functionally important in
virtually all lymphocytes examined; however, ablation of
Dicer selectively in T cells leads to spontaneous autoimmune
disease. This clinical outcome can be attributed to the
development of non-functional Treg and a scurfy-like autoim-
munity. The underlying mechanisms include miRNA regula-
tion of Treg proliferation, apoptosis, and lineage identity, as
well as an alteration of the Treg-defining transcriptome, FoxP3
expression, and ultimately suppressive function. As it has
become clear that T cell plasticity is far more common than
previously acknowledged [70–74], the importance of
miRNAs in regulating and maintaining T cell terminal
differentiation programs and a coordinated cytokine
response, especially under stress conditions, is likely to
play an essential role for proper immune homeostasis.
miRNA's Function as a Rheostat of Gene Expression
Whole proteome analyses have taught us that regulation of
protein abundance of individual target genes by miRNAs is
modest at best (often <50% of levels without miRNA
regulation) [25, 27]. Despite strong evolutionary conserva-
tion, a systematic ablation of 83% of known miRNAs in C.
elegans revealed that the majority of miRNAs was neither
required for viability nor development [75]. This can be
explained partially by functional redundancy because many
miRNAs exist in families with identical seed sequences,
and deletion of whole miRNA families can sometimes be
functionally rescued by re-expression of a single miRNA
[76, 77]. However, systematic ablation of whole families of
sequence-related miRNAs were frequently dispensable
when studying development or viability [77]. Nevertheless,
individual miRNAs are important regulators of gene
expression as absence or sometimes even only a reduction
of individual miRNAs or miRNA clusters can have
significant effects for the affected individual as demonstrat-
ed for miR-1 in the heart, miR-155 in the immune system,
and the miR-17∼92 cluster in lung, heart, and B cell
development [41, 43, 78, 79]. Thus, miRNAs are generally
fine-tuners or rheostats that sharpen gene expression, which
in some cases can control essential cellular functions [19,
25, 27]. So how can miRNAs have minor effects on
individual proteins yet be important regulators whose
absence in small subsets of immune cells (e.g., Treg)
results in a fatal disease? Computational algorithms for
conserved mammalian miRNAs predict an average of 300
targets per miRNA family [19]. This has experimentally
been validated as over-expression of a single tissue-specific
miRNA in HeLa cells down-regulated ∼100 transcripts
within 12 h. Over-expression of miR-124, a brain-enriched
miRNA, induced a shift towards a brain gene expression
signature, whereas over-expression of miR-1, a miRNA
enriched in muscle cells, induced a muscle-like mRNA
transcriptome [24]. Thus, miRNAs can rapidly and simul-
taneously regulate entire protein networks or signaling
pathways, thus shaping cell fate and identity. Furthermore,
almost 50% of target genes have two or more miRNA
binding sites for different miRNAs allowing for synergistic
effects [80] and vice-versa, several miRNAs can be induced
by the same stimulus synergizing and/or antagonizing
similar pathways [35].
The precise regulation of gene expression by miRNAs has
had an important impact on evolution [19, 80–82]. During
evolution, miRNA target genes either enriched or avoided
miRNA binding sites by changing their 3′ UTR length and/
or miRNA binding site density [80]. Ubiquitously
expressed genes tend to avoid miRNA regulation while
miRNA-regulated genes show tissue-specific expression. In
contrast, systematic analysis of miRNA binding sites in 3′
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UTRs in Drosophila revealed that the only tissue-specific
set of genes that avoids binding sites for a muscle-specific
miRNA (miR-1) are muscle-specific genes [80]. In other
words, by equipping non-muscle genes with binding sites
for the muscle-specific miR-1 and co-expressing miR-1,
Drosophila achieves muscle-specific gene expression by
repressing non-muscle genes. This mutual exclusion
might sharpen gene expression and confer robustness
[80].
miRNAs as Guardians of Immune Homeostasis
As up to 50% of protein-coding genes are regulated to some
degree by miRNAs, it is not surprising that autoimmunity
can be affected by dysregulated miRNA function [83–85].
However, miRNAs are important for regulating immunity
not only by the shear number of genes they regulate but
because they have balancing effects that are central to
immune homeostasis. A recent review suggested that only
three miRNAs together are predicted to target >50% of
lupus susceptibility genes [50]. The immune system has the
ability to react quickly and vigorously but must be
prevented from overshooting. After an infection has been
successfully controlled, a return to homeostatic conditions
must be achieved quickly; an accumulation of previously
activated cells need to be avoided. Balance is difficult to
achieve since small changes in the homeostatic equilibrium
can lead to significant consequences because of the
possibility of enormous amplification of rare precursors
which underlies the exponential nature of immune
responses [86]. Hence, balance is the key in the immune
system. As a result, discrimination of noise (i.e., non-
specific stimulation) from important information is critical.
Therefore, stochastic transcription needs to be repressed,
and parallel signaling through opposing cytokines needs to
be integrated using checkpoints and feedback mechanisms.
Since miRNAs are negative regulators of genetic networks,
they are well suited to achieve these tasks.
With a few exceptions, most autoimmune diseases are
genetically complex polygenic diseases. It is believed that
several defects at various checkpoints need to accumulate
before full-blown autoimmunity becomes apparent [87, 88].
Genome-wide association studies (GWAS) have been used
to identify multiple genetic risk factors in multigenic
immune diseases such as multiple sclerosis and type 1
diabetes (T1D) [89–92]. However, individual genes other
than the major histocompatibility cluster (MHC) genes
contribute to genetically complex diseases by odds ratios of
<2-fold [91], suggesting that genetic elements that function
as biologic “rheostats” are critical for the proper control of
the immune system consistent with a role for miRNAs as
potential key players. Importantly, in many instances, the
same GWAS-identified genes that fine tune autoimmune
susceptibility, result in catastrophic disease when fully
deficient (e.g., the interleukin-2 receptor alpha (CD25) or
the cytotoxicity T lymphocyte antigen 4 (CTLA-4)) [93,
94]. This implies that protein levels and functional activity
of key genes in the immune system need to be tightly
controlled. Indeed, haplo-insufficiency, i.e., reduction of
certain gene products by 50%, can predispose to autoim-
mune disease [95, 96]. In B cells, reducing the amount of c-
Myb by 25–50% results in impaired B cell development, an
observation also shown in mice mildly over-expressing
miR-150 where the transgenic miRNA targets c-Myb. On
the other hand, miR-150-deficient mice display increased
humoral immune responses. Hence, subtle changes in
expression of this miRNA and its target(s) can affect
normal development and immune function [39].
As outlined above, “sharpening” of mRNA expression
would allow the immune system to regulate gene expres-
sion in closely related cell types like lymphocyte subsets
during development or immune responses. Temporal
control of gene expression machinery in lymphocytes is
very tight [97, 98], and related cells of similar origin are
aligned spatially (in the thymus for instance) before
migrating to inflamed tissues. In addition, different cell
subsets (i.e., conventional T cells (Tconv) and Treg cells)
share similar transcriptomes and proteomes. With the
exception of very few genes, these differences are quanti-
tative rather than qualitative [99]. Thus, the abundance of
proteins in closely related cell subsets must be tightly
controlled, as small changes result in functionally distinct
lymphocyte populations that in many cases redirect the
cell to take on distinct or even opposing functions.
Therefore, miRNAs are candidates as critical regulators
of cell subset differentiation and maintenance and, perhaps
Tregs, which themselves function as rheostats of the
immune system, are poised to reflect the fine tuning
manifested by miRNAs. For instance, a limited compar-
ison of miRNA expression in nTreg, FoxP3-transduced,
and activated CD4+ murine T cells demonstrated quanti-
tative differences in expression of a common set of
miRNAs [34] suggesting that miRNAs regulate T lym-
phocyte fate specification. Of note, clonal heterogeneity
contributes to hematopoietic lineage choice and differen-
tiation [100], and small differences in protein concen-
trations or activity can decide over digital responses of cell
survival versus apoptosis [101]. miRNAs likely contribute
to immune homeostasis by tuning the proteome to reduce
the stochastic aspects of these important decisions. Thus,
we propose that miRNAs serve to sharpen the tran-
scriptome and proteome of lymphocyte subsets to help
define and maintain lineage identity, fine tune antigen-
receptor signaling, to set response thresholds, and help
convert analog into digital signals.
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What is the Evidence for Our Hypotheses
in the Immune System?
Immune Cell Lineage Stabilization by miRNAs
We have demonstrated that loss of Dicer exclusively in
nTreg led to increased loss of the lineage-defining
transcription factor FoxP3, and some FoxP3 expressing
Treg inappropriately secreted IFN-γ or IL-17 [67]. Several
reports have highlighted the plasticity in T cell subset
diversity, that genes can be “poised” for transcription, i.e.,
epigenetic changes associated with activation can be
present without detectable transcripts [70–72, 74, 102],
and fully differentiated T cell subsets can re-differentiate
under inflammatory or lymphopenic conditions [103–107].
Interestingly, individual Th subsets concomitantly have
activating and inactivating histone marks for transcription
factors, while histone marks at cytokine genes are mutually
exclusive, either activating or inactivating [102]. It has been
argued that mixed histone marking could allow for
plasticity, consistent with the notion that an additional layer
of negative regulation is necessary for lineage-determining
transcription factors. miRNAs could provide such regula-
tion. In this regard, nTreg have recently been proposed to
exist in Th1-, Th2-, and Th17-like subtypes that regulate
their respective effector T cell subsets as “class control”.
Th1, Th2, and Th17 subtypes of Tregs suppress Th1, Th2,
or Th17 effector cells, respectively, but fail to suppress the
other classes [108–110]. We propose that subsets of Treg-
expressed miRNAs suppress the generation of the other
subsets. In support of this model, Tbx21, GATA3, IRF4,
Stat6, and RORγt are targeted by at least one miRNA that
is highly expressed in Treg (www.targetscan.org and Jeker
& Bluestone, unpublished result). This type of miRNA
regulation has been termed “binary off-switch” as opposed
to the “tuning” regulation described above [19, 81].
miRNAs as Stabilizers of Genetic Networks Under Stress
such as Lymphopenia or Inflammation
It has been proposed that microRNAs reduce variation of
developmental programs and contribute to the development
of diverse regulatory networks, particularly under stress
conditions such as temperature fluctuations [111]. Such
network-stabilizing activity may be important as lympho-
cytes are constantly exposed to a changing microenviron-
ment during migration by exposure to various cytokines
and inflammation with increased blood flow and fluctua-
tions in body temperature. Therefore, miRNAs might both
regulate coordinated lymphocyte differentiation [35] and
stabilize it under environmental stress [70] (Fig. 1). As
highlighted above, Dicer-deficient Treg function was more
severely impaired in the presence of inflammation [68].
Similarly, under stress conditions, miR-155−/− Treg had a
competitive disadvantage, whereas germline deletion of
miR-155 resulted in a surprisingly mild Treg phenotype
under homeostatic conditions [42, 45]. In the immune stress
setting, miR-155 served to repress suppressor of cytokine
signaling 1 (SOCS1), an inhibitor of IL-2 signaling.
However, miR-155 is not always essential as IL-2 signaling
could be restored in miR-155-deficient Treg in vitro by
higher doses of IL-2. Yet, because Treg survival is strongly
dependent on IL-2 signaling [112, 113], fine tuning in this
pathway is critical. In humans and autoimmune disease
susceptible mice, multiple genes of the IL-2/IL-2R pathway
are known susceptibility genes for type 1 diabetes (T1D)
[89–91]. IL-2 treatment can lead to stabilization of FoxP3
expression in Treg, cure diabetes in mice [114], and restore
















Fig. 1 miRNA-mediated network stabilization against stress. A model
is presented based on a simple genetic network comprised of signaling
molecules S1 and S2 and transcription factor TF that is designed to
yield constant transcription irrespective of environmental cues. Under
homeostatic conditions, the genetic network leads to gene transcription
of gene A because the low miRNA/target mRNA ratio has no
measurable effect (a); however, inflammatory signals enhance activity
of signaling molecule S2 but also of miRNA miR which dampens the
signal S2 to ensure constant transcription of gene A despite
inflammation (b). The absence of miR miRNA buffering does not
affect the network under homeostatic conditions (c), but under
inflammatory conditions, leads to increased transcription of gene A
due to defective negative feedback regulation (d). Various modifica-
tions can be imagined where miRNAs are not induced but constantly
expressed to provide a protective buffer against overshooting protein
production of parts of the network. miRNAs may also act on more
complex networks with positive or negative feedback loops to
enhance, dampen, or stabilize signals. Thus, miRNAs increase
precision of genetic networks through fine-tuning expression of
network members
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miR-155 expression in Tregs is not essential to control
effector T cells under homeostatic conditions but is
important for competitive fitness under stress conditions.
miRNA-Mediated Immunologic Threshold Setting
miRNAs can also function to define a certain threshold for
signaling. A high miRNA/target ratio can completely
repress expression of the target despite transcription [19],
thus repressing stochastic transcriptional “noise” during cell
fate decisions. A lower miRNA/target ratio can lead to a
reduction of gene expression (tuning), and miRNAs can
repress expression of target genes without changing their
transcription. Arguably, the most sensitive and versatile
signal a lymphocyte can receive occurs through its antigen
receptor. Cognate peptide–MHC interactions with the
corresponding antigen-receptor leads to dramatic conse-
quences: survival and maturation versus death during
thymic selection; activation versus quiescence and tolerance
in the periphery; and effector cell fate versus memory cell
fate during an inflammatory response [116]. How a single
antigen receptor can sense an analogous spectrum of
ligands with various affinities and convert those into a
digital survival or death response has long remained
enigmatic. Among many regulatory pathways, miRNAs
add an additional layer of regulation by directly influencing
the TCR signal [117] and controlling regulatory pathways
(e.g., CD28, CTLA-4, PTEN [40], Cbl-b). Recently, several
models have been described that attempt to reconcile the
paradox that small affinity differences among TCR ligands
can have dramatic effects that create a digital response
[118–120]. In these models, minor changes in TCR signal
strength near the selection threshold are likely to result in
selection of a skewed and dangerous TCR repertoire with
potentially autoreactive lymphocytes. For instance, miR-
181a augments sensitivity to peptide antigens by targeting
multiple TCR-related phosphatases, thus affecting thymic
selection [117]. Moreover, miR-181a is involved in
preventing selection of “forbidden” clones [121]. Finally,
miRNA-mediated TCR tuning may contribute to Tconv
versus Treg differentiation choices as it has been demon-
strated that TCR signal strength regulates FoxP3 expression
[122, 123]. Individuals with autoimmune susceptibility
might have defective Ag-receptor signal dampening, result-
ing in a shift of the net activation towards the point of no
return for activation allowing a few cells to cross the
activation threshold [124] (Fig. 2a). As miRNAs can
contribute to setting thresholds, dysregulation of such key
miRNAs could underlie autoimmune pathogenesis. PTEN
expression, a negative regulator of PI3 kinase and hence
TCR signaling, is regulated by the miR-17∼92 cluster.
Transgenic overexpression of this miRNA cluster increases
T cell proliferation, likely due to enhanced TCR signaling
[40]. Moreover, the transgenic mice develop increased
autoantibody titers. In this regard, PTEN heterozygous mice
display an autoimmune phenotype [95], illustrating that
expression of this key-negative regulator of TCR signaling
needs to be tightly controlled. It remains to be determined
how tolerance is broken in these models and if the
autoantibodies are a consequence of uncontrolled prolifer-
ation or if the selection of self-reactive lymphocytes is also
affected. Nevertheless, overexpression of miR-17-5p, has
been described in CD4+ cells from patients with multiple
sclerosis [125] suggesting a potential role for miRNAs in
these settings.
In addition to shifting the activation threshold for a given
population (Fig. 2a), miRNAs might limit activation signals
by shaping the distribution of activation states of a
population of cells (Fig. 2b). In resistant individuals, this
layer of protection limits the number of cells that
“stochastically” cross the threshold of overt self-reactivity.
Absence of this buffering would increase the risk of some
cells reaching and crossing the tolerance threshold uninten-
tionally leading to autoimmunity.
Conversion of analog signals into digital responses is
key in the immune system. Digital responses are important
during thymic selection [120]. miRNAs may play a key role
in determining the outcome of these events (Fig. 3).
miRNAs could prevent or delay a selecting signal under
normal conditions; however, when the ratio of miRNA/
target is reduced due to target activation by the selecting
stimulus, the miRNA no longer suppresses the target
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Ag receptor signal strength for self peptides-     -
Fig. 2 miRNA-mediated threshold setting in the immune system:
preventing unintentional lymphocyte activation. The net activation
signal for self-peptides of T cells varies physiologically. a The
threshold for activation is not reached by any cell of a given T cell
population in healthy (black line) individuals perhaps dependent on
TCR dampening by miRNAs. In susceptible individuals (grey line)
with impaired miRNA-mediated TCR dampening, the whole T cell
population is shifted to the right such that a few cells cross the
threshold (dashed line) and become activated to start an autoimmune
response. b Alternatively, rather than decreasing net activation of the
whole T cell population, the expression of miRNAs reshape the
receptor activation curve such that a more narrow range of signals
trigger T cells. In this scenario, loss of miRNA expression may
broaden the edge of the distribution such that a subset of cells crosses
the threshold for activation
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efficiently allowing a response. Additional regulatory loops
can lead to a very sharp response that overcomes the
threshold set by the miRNA feedback. Another set of
miRNAs then prevents the response from overshooting its
threshold by setting a maximum response level. The effect
of a stimulating analog signal into a cell is illustrated in
Fig. 3. The presence of miRNAs allows the cell's response
to convert into a digital outcome. Absence of such
sharpening of the response could result in a skewed Ag-
receptor repertoire or dysregulated T cell activation and
survival, ultimately contributing to autoimmune disease.
Potential Diagnostic and Therapeutic Applications
of RNAi, miRNAs, and Artificial Small RNAs
(or mimetics)
Several diseases have been probed for differential miRNA
expression compared to healthy individuals. miRNA
dysregulation and potential function in rheumatoid arthritis
and lupus erythematosus has recently been reviewed [126].
miR-146a is upregulated in peripheral blood mononuclear
cell (PBMCs) from rheumatoid arthritis patients [127], and
patients suffering from multiple sclerosis differentially
express miRNAs in their PBMCs and CD4+ T cells [125,
128, 129]. It will also be important to test if accumulations
of mutations in miRNA loci (or their mRNA targets) are
found in samples from patients with autoimmune disease
similar to cancer genomes [130, 131]. Thus, pinpointing
individual miRNAs or miRNA signatures dysregulated in
autoimmune diseases will be further studied, seeking
mechanistic insight into disease pathogenesis, facilitating
clinical diagnosis and/or monitoring disease activity, and
miRNA modulators might be considered as therapeutics.
It will be important to find the miRNAs that are
responsible for stabilizing FoxP3 [67] as these cells are
major regulators of autoimmunity. The design of miRNA
mimics or inhibitors that stabilize the Treg phenotype may
be useful in the treatment of autoimmune diseases as FoxP3
instability has been correlated to autoimmune inflammation
[104, 132]. In this regard, small RNA-based therapies
might become available in the near future and such
therapies might become cell-type specific [133, 134].
Experimental data suggest that small RNA-based therapeu-
tics can be extremely challenging but powerful [135–138].
Recently, a clinical phase Ia study with small synthetic
RNAs directed at miR-122 was initiated as a treatment for
hepatitis C (www.clinicaltrials.gov NCT00979927). In
addition, endogenous miRNA expression is also being
targeted to guide transgene expression [139]. Thus, miRNA
technology is being exploited on many levels including
gene therapy applications where a proof of principle study
demonstrated that miRNA-guided gene therapy can induce
T cell tolerance [140].
Conclusions
It is now clearly established that miRNAs are critical for
proper immune regulation. However, our knowledge of the
contribution and mechanisms of individual miRNAs in
autoimmune disease and immunity is at a very early stage.
Despite lymphocytes being one of the best characterized
cell types in mice and humans with extensive knowledge
about genetic programs regulating lineage differentiation, a
comprehensive small RNA signature is not known for
many types of immune cells, with a few exceptions.
However, the rapid pace of technologic advance to assess
even a single cell's genome-wide transcription combined with
sensitive techniques to measure entire proteomes will deliver
exciting insight in the coming years. By regulating immune
cell development and lineage stabilization, sharpening gene
expression, setting thresholds, buffering fluctuations of gene
expression to balance genetic networks under stress,
miRNAs provide a protective layer to immune homeostasis.
Thus, elimination of individual miRNA function will likely
not lead to full blown autoimmune disease but may very well
increase the susceptibility to autoimmune disease. Thus,
miRNAs are likely pieces in the mosaic of autoimmune
pathogenesis. Without any doubt, the next decade will be
exciting when we start to understand how miRNAs function
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Fig. 3 miRNAs can facilitate the conversion of analog signals into
digital responses. Through sharpening of gene expression, miRNAs
could help to convert analog signals into digital signals. In this
scenario, a low stimulus does not lead to a response due to repression
by a miRNA (miR-a). If the ratio of miRNA/target(s) decreases
because the target is induced, a response occurs rapidly because
positive feedback loops have been activated. Overshooting of the
response is prevented by other miRNAs (miR-b) that set a threshold at
higher protein expression levels limiting the maximum net response.
This allows responses to convert from analog into digital signals
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